Recent Updates
Recently added Catalysts
ALGS Neutral Sentiment

Discovery and Preclinical Profile of ALG-055009, a Potent and Selective Thyroid Hormone

Monday, September 2, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article provides an overview of ALG-055009, a selective thyroid hormone compound developed by Aligos Therapeutics. It discusses the company's management, pipeline, and various clinical trials related to chronic HBV infection. However, specific details about the discovery and preclinical profile of ALG-055009 are not included.
Price reaction · baseline $12.68 (2024-08-30 close) · clean, no other ALGS news in the window
day 0 close
-5.6%
day 1 · peak
-7.4%
day 3
-1.3%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR
ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare Aligos Therapeutics thyroid hormone chronic HBV clinical trials preclinical profile
Last updated: Sep 2, 2024

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →